Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653943 | 1.00 | PPARG (0.42) | PPARGPTGS1HTR6CNR1RXRA | |
| SCHEMBL9621642 | 0.89 | PPARG (0.54) | PPARGPTGS1HTR6CNR1RXRA | |
| SCHEMBL2541623 | 0.86 | RXRA (0.41) | PPARGPTGS1HTR6CNR1RXRA | |
| SCHEMBL27729340 | 0.77 | PPARG (0.53) | PPARGPTGS1RXRA | |
| SCHEMBL2541626 | 0.75 | PPARG (0.46) | PPARGPTGS1RXRA | |
| SCHEMBL14301060 | 0.74 | HTR6 (0.36) | HTR6CNR1 | |
| SCHEMBL4548508 | 0.74 | PPARG (0.73) | PPARGPTGS1RXRA | |
| SCHEMBL11884029 | 0.74 | KMT2A (0.37) | PPARGPTGS1HTR6 | |
| SCHEMBL27754431 | 0.72 | PPARG (0.40) | PPARGPTGS1RXRA | |
| SCHEMBL4548560 | 0.72 | PPARG (0.56) | PPARGPTGS1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0342682-A2 | Hydroxamate derivatives of selected nonsteroidal anti-inflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition | WARNER-LAMBERT COMPANY (US) | 1989-11-23 | — | — | EP | claimed |
| US-20070244122-A1 | Derivatives of sulindac, use thereof and preparation thereof | SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZATION AND INTELLECTUAL PROPERTY (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244122-A1 | Derivatives of sulindac, use thereof and preparation thereof | SULT2A1, PTGES3, SULT1A1 | PPARG 244/4885PTGS1 6/4885HTR6 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.